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Abstract
Background: Graves’ disease is a unique conglomeration of cardiovascular, neurological, ophthalmological, and other 
systemic manifestations. In this study we have tried to explore the psychiatric dimensions of this disease.
Aims: This study attempted to explore clinical features, types, and treatment outcome of psychiatric disturbances in 
Graves disease.
Study Design: This is a purposive study following the criteria of DSM IV.
Materials and Methods: A total of 36 adult patients of newly diagnosed Graves disease and 30 age- and sex-matched 
controls were included. Data enumerated were age, sex, date of admission, analysis of psychiatric signs, and symptoms 
by one independent observer, diagnostic categorization, effect of treatment, and outcome. Follow-up evaluation was 
done after 1 year.
Statistical Analysis: Statistical analysis was done by the standard error of difference, the chi-square test, and paired 
Student’s T-test.
Results: Among 36 patients 32 were female and 4 were male. Fifteen patients (41.67%) were diagnosed with generalized 
anxiety disorders (GAD), 6 (16.67%) with mood disorder, 6 (16.67%) with obsessive compulsive disorder (OCD), and 2 
each with personality disorder and schizophreniform disorder. The common symptoms were insomnia, irritability, and 
anxiety. The Frequency of GAD was statistically more significant in the Graves disease group in comparison to control. 
Fourteen patients agreed to take both antithyroid and antipsychotropic medications (group 1). The rest were treated with 
only antithyroid drug (group 2). There was significant improvement in both groups and no difference between the groups.
Conclusion: The prevalence of certain psychiatric manifestations in Graves’ disease was significantly higher than 
in the control group. There was no significant difference between therapy with antithyroid drugs and combination of 
antithyroid with psychotropic medications.
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Introduction
Graves’ disease is a unique conglomeration of cardiovascular, 
neurological, ophthalmological, and other systemic 
manifestations. The physical concomitants of the disease have 
been extensively dealt with over years. The disease might have 
been associated with psychological changes which could have 
a crucial impact on the overall well-being and quality of life of 
these patients. Impaired quality of life leads to a vicious cycle of 
greater psychological distress and poor productivity.[1] Therefore 
in this study we have tried to explore the symptomatology and 
types of psychiatric illness in Graves’ disease and to evaluate 
therapeutic outcomes in such dysfunction.
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Aims
1. To explore the symptomatology and types of psychiatric 
illness in Graves’ disease.
2. To evaluate therapeutic outcome in such dysfunction.
Materials and Methods
The study was conducted in a Medical College and hospital 
in Eastern India from January 2008 to December 2010. 
Thirty-six newly diagnosed cases of Graves’ disease were 
taken from outdoor departments. This is a purposive study 
following the criteria of DSM IV. According to DSM IV 
(the American Psychiatric Association Classification Book) 
a mental disorder due to a general medical condition is 
characterized by the presence of mental symptoms that 
are judged to be the direct psychological consequence of 
general medical condition - in this case Graves’ disease. 
Purposive sampling targets a particular group of people. 
When the desired population for the study is rare or very 
difficult to locate and recruit for a study, purposive sampling 
may be the only option. But it might introduce a fallacy of 
bias. To eliminate that, patients having the first episode of 
psychiatric illness were taken as both cases and controls. 
Informed consent was taken from all patients in accordance 
with ethical standards of local committee as well as the 
Helsinki Declaration of 1975 as revised in 2000. Diagnosis 
was based on clinical examinations, T3, T4, TSH levels, 
and anti-TPO antibody levels. Thirty age- and sex-matched 
controls were chosen from the same outdoor. DSM IV 
criteria clearly suggested “The disturbance is not due to 
the direct physiological effects of a substance (e.g., a drug 
of abuse, a medication) or a general, medical condition.”
Therefore exclusion criteria for both case and control groups 
were patients with neurological disorder prior psychiatric 
disorder, other endocrine disorders and substance abuse and 
patients with previous psychiatric diseases. Controls were 
lost to follow-up more than cases, and many could not afford 
medications, so our control size is lower in comparison to cases.
Psychiatric assessment was done by an independent observer, 
our psychiatrist. Severity of psychiatric illness was gauged 
by specific rating scales like HAM A (Hamilton rating scale 
for anxiety),[2] MADRS (Montgomery Asberg depression 
rating scale),[3] Y BOCS (Yale Brown obsessive compulsive 
scale),[4] etc. Follow-up was done at 6 months and 1 year. 
Scores to see the degree of improvement by different scales 
at diagnosis and final follow-up were compared.
For evaluation of therapeutic outcome Graves’ disease 
patients were divided into two groups. Group 1 consisted 
of those who consented to take both antithyroid drugs and 
psychotropic medications. Group 2 received only antithyroid 
drugs. Both groups were on beta-blockers.
Statistical analysis
Significance of difference between proportions was 
evaluated by the standard error of difference. Comparison 
of degree of improvement with therapy was calculated by 
the paired Student’s T-Test and chi-square test. P <0.05 
was considered significant
Result
A total of 36 newly diagnosed Graves’ disease patients were 
included in the study. There were 32 female and 4 male 
patients. The age ranged from 18 to 60 years, with mean 
age of 35.8 (5) years. In the control group age ranged from 
20 to 56 years, with mean age of 36.3 (6.5) years. Controls 
were matched for age, education, and coming from the same 
locality. They were not the relatives of the patient.
The common symptoms noted among patients with 
Graves’ disease were insomnia (80%), anxiety (62%), 
and psychomotor agitation (50%). A sad mood, poor self-
esteem, and fragile interpersonal relationships were also 
omnipresent. As interpreted by our psychiatrist generalized 
anxiety disorder, mood disorder, obsessive compulsive, 
personality disorder, and bipolar disorder were detected 
in the Graves disease group [Figure 1]. The patients 
with latter two disorders on subsequent in depth analysis 
were seen to have subtle manifestations of the problems 
right from childhood. Hence they were excluded from 
subsequent calculations. Among Graves’ patients 31 out 
of 36 had some form of psychiatric manifestations which 
was highly statistically significant (P <0.05). A total 
of 41.67% (15) had GAD, 16.67% (6) had mood, and 
16.67% (6) obsessive compulsive disorder. In the control 
group GAD was found in 13.3% (4), mood disorder in 
10% (3), and OCD in 3.3% (1). In comparison with control 
group on the basis of the prevalence only GAD was found 
to be significantly higher while MD and OCD was more 
or less comparable [Table 1].
The next part of our study involved assessment of 
improvement with therapy in Graves disease cases. Patients 
who consented to take both antithyroid and psychiatric 
medication were put in group 1, those on only antithyroid 
drugs comprised group 2.
Figure 1: Diagnostic categorization
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disorder, and depression.[6] Apart from these there have 
been documentations of borderline personality disorders, 
schizophreniform disorders, and frank psychosis.[7] In our 
study GAD was the most common abnormality among newly 
diagnosed cases. Other two common accompaniments were 
mood disorders and obsessive compulsive disorders (OCD).
The most discriminating symptoms found were insomnia, 
psychomotor agitation, and increased tension. Poor 
concentration, lack of self-esteem, poor social relationships 
were also widely prevalent. All these leads to deficiency in 
productivity, loss of work hours, producing a vicious cycle 
of more depression and anxiety.[8]
A study by Elberling quantitated healh-related quality of life 
(HRQOL) in newly diagnosed cases of Graves’ disease. They 
opined that there was significant impairment in HRQOL 
scores (by SF 36 Questionnaire) due to all these psychiatric 
illnesses at the acute phase. However no correlation 
was found between TSH levels and degree of psychiatric 
morbidity.[9,10]
Another interesting angle to the problem that was 
demonstrated by Farid et al. was the relation of ophthalmopathy 
with mood disorder. It was postulated that disfigurement was 
a major cause of depression and poor self-esteem.[11-13]
Our observations show prevalence of certain psychiatric 
manifestations in Graves’ disease was significantly higher 
than in the control group. There was no significant 
difference between therapy with antithyroid drugs and 
combination of antithyroid with psychotropic medications.
Existing information regarding the effect of therapy in such 
cases is slightly conflicting. Some studies have documented 
“relatively prompt resolution of the patients” dysfunctional 
behavior with treatment.[14] Others have shown unremitting 
psychiatric illness in 50% cases which persisted from several 
months to even a decade after a presentation.[15] Thomson et 
al. found that patients hospitalized with hyperthyroidism were 
at a greater risk of re admission with depressive episodes.[16]
Figure 2: Group allocation Figure 3: Contingency table
Table 1: Diagnostic comparison
Diagnosis Graves disease patients % Controls %
GAD 41.67 13.3 P<0.5
MD 16.67 10 P>0.5
OCD 16.67 3.3 P>0.5
GAD = Generalized anxiety disorder; MD = Mood disorder;  
OCD = Obsessive compulsive disorder.
Table 2: Degree of improvement
Score Group 1 Group 2
HAM A <14 6 5
MADRS <6 2 2
Y BOCS <10 3 2
Total no. of patients with 
normal scores
11 9
HAMA = Hamilton rating scale for anxiety; MADRS = Montgomery Asberg 
depression rating scale; Y BOCS = Yale brown obsessive compulsive scale.
The group allocation for each diagnosed psychiatric illness is 
shown in [Figure 2]. Out of 31 patients showing psychiatric 
morbidity 11 patients had normal scores at the end of 1 
year in group 1 while in group 2, 9 patients became normal 
[Table 2]. By applying the chi-square test there was no 
significant difference between the effects of two modes of 
therapy [Figure 3]. However irrespective of mode of therapy 
it was evident that our patients improved significantly at the 
end of 1 year. The mean HAM A score of 15 cases of GAD 
was 24.6 (3.6) at diagnosis. At the end of 1 year, it was 11.1 
(2.96). For patients with depression mean MADRS score 
was 27 (4) at diagnosis which came down to 7.8 (4.1) at 
1-year follow-up. For the obsessive compulsive the respective 
Y BOCS scores were 16.16 (2.5) and 8.3 (1.3). Applying 
the Student t-test for each of these classes of patients the 
decrease in scores was statistically significant (P < 0.001).
Discussion
Psychiatric illness is a well-documented concomitant of 
Graves’ disease. Long-term studies spanning over 20 years by 
Brownlie et al. showed an incidence of affective disorders well 
above chance cooccurrence.[5] The most common ailments 
detected were generalized anxiety disorder (GAD), bipolar 
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The finding that there was no significant difference between 
two treatment groups mentioned above needs to be further 
explored. Our study suffers from limited number of cases 
as many were lost to follow-up, and many could not afford 
all medications.
In conclusion psychiatric illnesses, chiefly, generalized 
anxiety disorder and mood disorders are highly prevalent 
among patients of Graves’ disease. There is marked 
improvement with antithyroid medications. The importance 
of psychiatric consultation in this disease cannot be 
overlooked.
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